The effect of TTF-1 expression on ipsilateral mediastinal nodal (N2) metastases in primary adenocarcinoma of the lung

Wspolczesna Onkologia

Volumn 16, Issue 6, 2012, Pages 516-519

  Samancilar, Ozgur ^a   Kaya, Seyda Ors ^a   Ceylan, Kenan Can ^a   Usluer, Ozan ^a   Yener, Ali Galip ^a  

^a Dr Suat Seren Chest Diseases and Thoracic Surgery Research and Training Hospital   (Turkey)

Author keywords

Adenocarcinoma; Lung; N2; Thyroid transcription factor 1

Indexed keywords

THYROID TRANSCRIPTION FACTOR 1;

ADULT; ARTICLE; CANCER SURGERY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG RESECTION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; MEDIASTINUM LYMPH NODE; PATIENT CODING; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 84872549807     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.32484     Document Type: Article

References (27)

1. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging for lung cancer. Ann Thorac Cardivasc Surg 2009; 15: 4-9.
2. Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010; 375: 1267-77.
3. Pignon JP, Tribodet H, Scagliotti GV, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-9.
4. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043-51.
5. Turhan K, Samancilar O, Cagirici U, Goksel T, Nart D, Cakan A, Cok G. The effect of blood vessel invasion on prognosis of operated stage I non-small cell lung cancer patients. Thorac Cardiovasc Surg 2010; 58: 28-31.
6. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. Chest 2011; 140: 1494-502.
7. Ucvet A, Kul C, Gursoy S, Erbaycu AE, Kaya SO, Dinc ZA, Yucel N. Prognostic value of epithelial growth factor receptor, vascular endothelial growth factor, E-cadherin, and p120 catenin in resected non-small cell lung carcinoma. Arch Bronconeumol 2011; 47: 397-402.
8. Kobayashi N, Toyooka S, Soh J, et al. Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less. J Thorac Oncol 2007; 2: 808-12. (Pubitemid 47361021)
9. Meert AP, Martin B, Paesmans M, et al. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 2003; 89: 959-65. (Pubitemid 37239194)
10. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, Lafitte JJ, Sculier JP. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004; 91: 2018-25. (Pubitemid 40128768)
11. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92: 131-9. (Pubitemid 40188446)
12. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001; 18: 705-19. (Pubitemid 33040631)
13. Kasprzyk M, Dyszkiewicz W, Roszak M, Gabryel P, Gałȩcki B. Are preoperative acute phase proteins serum levels associated with clinical outcome in non-small cell lung cancer patients? Kardiochirur Torakochirur Pol 2010; 7: 415-20.
14. Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, Lafitte JJ, Sculier JP. Thyroid transcription factor 1 - a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol 2006; 17: 1673-6. (Pubitemid 44680888)
15. Ordóñez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol 2000; 7: 123-7.
16. Moldvay J, Jackel M, Bogos K, Soltész I, Agócs L, Kovács G, Schaff Z. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res 2004; 10: 85-8. (Pubitemid 38915600)
17. Hecht JL, Pinkus JL, Weinstein LJ, Pinkus GS. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. Am J Clin Pathol 2001; 116: 483-88. (Pubitemid 34450281)
18. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol 2001; 25: 363-72. (Pubitemid 32175139)
19. Puglisi F, Barbone F, Damante G, Bruckbauer M, Di Lauro V, Beltrami CA, Di Loreto C. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. Mod Pathol 1999; 12: 318-24. (Pubitemid 29133854)
20. Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond) 2009; 116: 27-35.
21. Martins SJ, Takagaki TY, Silva AG, Gallo CP, Silva FB, Capelozzi VL. Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer 2009; 64: 105-9.
22. Saito RA, Watabe T, Horiguchi K, Kohyama T, Saitoh M, Nagase T, Miyazono K. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Cancer Res 2009; 69: 2783-91.
23. Bai XY, Shen H. Quantitative study of thyroid transcription factor-1 protein expression in lung carcinoma cell nucleus by tissue microarray. Nan Fang Yi Ke Da Xue Xue Bao 2006; 26: 1423-6.
24. Bai XY, Shen H. Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28: 20-5.
25. Barletta JA, Perner S, Iafrate AJ, et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med 2009; 13: 1977-86.
26. Yoon SO, Kim YT, Jung KC, Jeon YK, Kim BH, Kim CW. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer 2011; 71: 209-16.
27. Altaner S, Yoruk Y, Tokatli F, Koçak Z, Tosun B, Guresci S, Kutlu K. The correlation between TTF-1 immunoreactivity and the occurrence of lymph node metastases in patients with lung cancer. Tumori 2006; 92: 323-6. (Pubitemid 44529474)